Stella Diagnostics Stock

Stella Diagnostics, Inc. operates as a molecular diagnostics-based company. The company focuses on improving patient management strategies for over 67 million people living with severe esophageal disease. The company’s clinical assay will offer physicians insight into the molecular properties of their patients' tissue to determine if the disease is stable, progressing or turning cancerous. The company is developing first-line diagnostic tools that provides superior molecular information for providers as compared to the standard screening protocols.

History

The company was formerly known as JMP Properties, Inc. and changed its name to Stella Diagnostics, Inc. in April 2021.